Immune compatibility for off-the-shelf, allogeneic cell therapies
We have established and continue to grow a library of distinct HLA-homozygous iPSC lines. Produced under GMP from rigorously selected cord blood units, this library is a universal platform for off-the-shelf iPSC-based therapies.
Why use HLAh cell lines?
- - Significantly reduced immunogenicity permits allogeneic cell therapies
- - Each cell line is inexhaustible
- - Each cell line potentially matches thousands to millions of recipients
- - Off-the-shelf model enables faster, more cost-effective therapy development
Overcoming limitations of autologous cell therapies
Groundbreaking work by Shinya Yamanaka and James Thomson launched the use of a patient’s own (autologous) induced pluripotent cells to treat degenerative diseases. With broad development potential, these cells can replace damaged tissue in conditions like macular degeneration, myocardial infarction, diabetes, Parkinson’s disease, and muscular dystrophy.
However, autologous therapies that produce cell lines “from the patient for the patient” are expensive, time-consuming, and often require long-term immune suppression.
allogeneic approaches, in contrast, enable off-the-shelf therapeutics with several recipients per cell line and fast turnaround. Key is a strategy to reduce immune rejection of the cells.
RHEINCELL uses cutting-edge iPSC technology to reprogram clinically approved cord blood collections into iPSC lines that are immune compatible with a wide population.
HLA-homozygous cell lines: matching more recipients, helping more patients
Collectively, a library of HLAh cell lines matches the genotype of thousands to millions of patients in a population. Given our location, our HLAh iPSC library covers European and North American Caucasians best.
HLA (human leukocyte antigen) genes are major determinants of tissue recognition and rejection in the body. The thousands of HLA variants in the population complicate cell donor-recipient matching and often lead to immune rejection.
HLA-homozygous (HLAh) donors are a rare exception. Carrying a single HLA haplotype, HLAh cell lines from their starting material genetically match a statistically larger portion of the population.